Literature DB >> 28668827

A Novel mTOR Inhibitor; Anthracimycin for the Treatment of Human Hepatocellular Carcinoma.

Tomoyuki Hayashi1, Taro Yamashita2,3, Hikari Okada1, Naoki Oishi1, Hajime Sunagozaka1, Kouki Nio1, Takehiro Hayashi1, Yasumasa Hara1, Yoshiro Asahina1, Mariko Yoshida1, Tomomi Hashiba1, Tsuyoshi Suda1, Takayoshi Shirasaki1, Yasuhiro Igarashi4, Koji Miyanouchi5, Tatsuya Yamashita1, Masao Honda1, Shuichi Kaneko1.   

Abstract

BACKGROUND/AIM: Anthracimycin, a secondary metabolite of Streptomyces, has been shown to inhibit the invasion of certain cancer cell lines.
MATERIALS AND METHODS: In this study we evaluated the effect of anthracimycin on cell growth and signaling pathways in hepatocellular carcinoma (HCC).
RESULTS: Anthracimycin suppressed cell proliferation and motility and induced apoptosis in human HCC cell lines. Furthermore, anthracimycin had no effect on the enrichment of EpCAM-high liver cancer stem cells (CSCs), while fluorouracil dramatically enriched the CSCs with activation of the stemness-related genes EPCAM and SOX9 in HuH7 cells. Mechanistically, anthracimycin suppressed mammalian target of rapamycin (mTOR) signaling, and was most effective at inhibiting HCC cell proliferation with mTOR activation.
CONCLUSION: Anthracimycin is a novel mTOR inhibitor capable of suppressing the proliferation of CSCs and non-CSCs equally well in HCC, and it is suggested that anthracimycin could be effective in the eradication of HCC associated with mTOR-signaling activation. Copyright
© 2017, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Anthracimycin; cancer stem cells; hepatocellular carcinoma; mammalian target of rapamycin

Mesh:

Substances:

Year:  2017        PMID: 28668827     DOI: 10.21873/anticanres.11706

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  7 in total

1.  Asymmetric Total Synthesis of the Naturally Occurring Antibiotic Anthracimycin.

Authors:  Emma K Davison; Jared L Freeman; Wanli Zhang; William M Wuest; Daniel P Furkert; Margaret A Brimble
Journal:  Org Lett       Date:  2020-06-29       Impact factor: 6.005

2.  2-Epi-anthracimycin, a new cytotoxic agent from the marine-derived actinomycete Streptomyces sp. OPMA00631.

Authors:  Takashi Fukuda; Kenichiro Nagai; Akihiko Kanamoto; Hiroshi Tomoda
Journal:  J Antibiot (Tokyo)       Date:  2020-05-13       Impact factor: 2.649

Review 3.  Synthesis and biological evaluation of rapamycin-derived, next generation small molecules.

Authors:  Shiva Krishna Reddy Guduru; Prabhat Arya
Journal:  Medchemcomm       Date:  2017-11-22       Impact factor: 3.597

4.  Inhibitory and ameliorative effect of heliomycin derived from actinomycete on induced hepatocellular carcinoma in rats.

Authors:  Ahmed S Alazzouni; Abdulla A Mahmoud; Mohamed M Omran; Ehab A Essawy; Mohga S Abdalla; Mohamed S Abdelfattah
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2021-01-08       Impact factor: 3.000

5.  Streptomyces sp metabolite(s) promotes Bax mediated intrinsic apoptosis and autophagy involving inhibition of mTOR pathway in cervical cancer cell lines.

Authors:  Vipin Mohan Dan; Balaji Muralikrishnan; Rahul Sanawar; Vinodh J S; Bhushan Bapusaheb Burkul; Kalanghad Puthankalam Srinivas; Asha Lekshmi; N S Pradeep; Syed G Dastager; B Santhakumari; Thankayyan R Santhoshkumar; R Ajay Kumar; Madhavan Radhakrishna Pillai
Journal:  Sci Rep       Date:  2018-02-12       Impact factor: 4.379

6.  Isolation and Identification of an Anthracimycin Analogue from Nocardiopsis kunsanensis, a Halophile from a Saltern, by Genomic Mining Strategy.

Authors:  Fernanda L Sirota; Falicia Goh; Kia-Ngee Low; Lay-Kien Yang; Sharon C Crasta; Birgit Eisenhaber; Frank Eisenhaber; Yoganathan Kanagasundaram; Siew Bee Ng
Journal:  J Genomics       Date:  2018-05-21

7.  Anthracimycin B, a Potent Antibiotic against Gram-Positive Bacteria Isolated from Cultures of the Deep-Sea Actinomycete Streptomyces cyaneofuscatus M-169.

Authors:  Víctor Rodríguez; Jesús Martín; Aida Sarmiento-Vizcaíno; Mercedes de la Cruz; Luis A García; Gloria Blanco; Fernando Reyes
Journal:  Mar Drugs       Date:  2018-10-25       Impact factor: 5.118

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.